Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: a meta-analysis

References

• Shadpour P, Zamani M, Aghaalikhani N, et al. Inflammatory cytokines in bladder cancer. J Cell Physiol. 2019;234:14489–14499. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Magers MJ, Lopez-Beltran A, Montironi R, et al. Staging of bladder cancer. Histopathology. 2019;74:112–134.
   PubMed Web of Science ®Google Scholar
• Tan WS, Tan WP, Tan MY, et al. Novel urinary biomarkers for the detection of bladder cancer: A systematic review. Cancer Treat Rev. 2018;69:39–52.
   PubMed Web of Science ®Google Scholar
• Yu Y, Cao H, Zhang M, et al. Prognostic value of DNA methylation for bladder cancer. Clin Chim Acta. 2018;484:207–212.
   PubMed Web of Science ®Google Scholar
• Kata SG, Zreik A, Ahmad S, et al. Concurrent bladder cancer in patients undergoing photodynamic diagnostic ureterorenoscopy: how many lesions do we miss under white light cystoscopy? Cent European J Urol. 2016;69:334–340.
   PubMed Web of Science ®Google Scholar
• Qie Y, Hu H, Tian D, et al. The value of extensive transurethral resection in the diagnosis and treatment of nonmuscle invasive bladder cancer with respect to recurrence at the first follow-up cystoscopy. Onco Targets Ther. 2016;9:2019–2025.
   PubMed Web of Science ®Google Scholar
• Liu R, Tian Z, Wang J, et al. Evaluation of acridine orange fluorescence in exfoliative urinary cytology for diagnosing bladder carcinoma. Int Urol Nephrol. 2012;44:1375–1382.
   PubMed Web of Science ®Google Scholar
• Loh CS, Spedding AV, Ashworth MT, et al. The value of exfoliative urine cytology in combination with flexible cystoscopy in the diagnosis of recurrent transitional cell carcinoma of the urinary bladder. Br J Urol. 1996;77:655–658.
   PubMedGoogle Scholar
• Rink M, Schwarzenbach H, Riethdorf S, et al. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. World J Urol. 2018. Epub ahead of print.
   Google Scholar
• Zhang Z, Fan W, Deng Q, et al. The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies. Oncotarget. 2017;8:59527–59538.
   PubMedGoogle Scholar
• Street JM, Yuen PS, Star RA. Bioactive exosomes: possibilities for diagnosis and management of bladder cancer. J Urol. 2014;192:297–298.
   PubMed Web of Science ®Google Scholar
• Szarvas T, Kovalszky I, Bedi K, et al. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncol Rep. 2007;18:405–409.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–536.
   PubMed Web of Science ®Google Scholar
• Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–1135.
   PubMed Web of Science ®Google Scholar
• Brisuda A, Pazourkova E, Soukup V, et al. Urinary cell-free DNA quantifcation as non-invasive biomarker in patients with bladder cancer. Urol Int. 2016;96:25–31.
   PubMed Web of Science ®Google Scholar
• Kim YH, Yan C, Lee IS, et al. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer. Investig Clin Urol. 2016;57:106–112.
   PubMed Web of Science ®Google Scholar
• Casadio V, Calistri D, Tebaldi M, et al. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol. 2013;31:1744–1750.
   PubMed Web of Science ®Google Scholar
• Ellinger J, Muller DC, Muller SC, et al. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol. 2012;30:509–515.
   PubMed Web of Science ®Google Scholar
• Hauser S, Kogej M, Fechner G, et al. Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res. 2012;32:3119–3124.
   PubMed Web of Science ®Google Scholar
• Ellinger J, Bastian PJ, Ellinger N, et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett. 2008;264:274–280.
   PubMed Web of Science ®Google Scholar
• Chang HW, Tsui KH, Shen LC, et al. Urinary cell-free DNA as a potential tumor marker for bladder cancer. Int J Biol Markers. 2007;22:287–294.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhu T, Wang Z, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specifc detection of bladder cancer. Clin Cancer Res. 2007;13:7296–7304.
   PubMed Web of Science ®Google Scholar
• Chan MW, Chan LW, Tang NL, et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer. 2003;104:611–616.
   PubMed Web of Science ®Google Scholar
• Valenzuela MT, Galisteo R, Zuluaga A, et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol. 2002;42:628–630.
   Web of Science ®Google Scholar
• Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–322.
   PubMed Web of Science ®Google Scholar
• Kim PH, Cha EK, Sfakianos JP, et al. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur Urol. 2015;67:198–201.
   PubMed Web of Science ®Google Scholar
• Pietzak EJ, Bagrodia A, Cha EK, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol. 2017;72:952–959.
   PubMed Web of Science ®Google Scholar
• Scott SN, Ostrovnaya I, Lin CM, et al. Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. Cancer Cytopathol. 2017;125:416–426.
   PubMed Web of Science ®Google Scholar
• Bunjevac A, Gabaj NN, Miler M, et al. Preanalytics of urine sediment examination: effect of relative centrifugal force, tube type, volume of sample and supernatant removal. Biochem Med (Zagreb). 2018;28:010707.
   PubMed Web of Science ®Google Scholar
• Yan L, Chen Y, Zhou J, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int J Infect Dis. 2018;67:92–97.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhai C, Su C, et al. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis. Lung Cancer. 2016;100:63–70.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Li W, Leng B, et al. Circulating cell free DNA as the diagnostic marker for ovarian cancer: a systematic review and meta-analysis. PLoS One. 2016;11:e0155495.
   PubMedGoogle Scholar